For this reason our patient was given recombinant human FVIII, a pro-hemostatic agent originally designed for the treatment of alloimmune hemophiliacs, as well as CTX to better restrain the inflammatory reactivation of SLE. Here, F8 is linked to systemic lupus erythematosus.